top of page
News, Events and Updates
Search
New Phase IIb/III Clinical Data Demonstrates Over Three Years of Continuous Treatment with Oral Blarcamesine to Significantly Benefit Early Alzheimer’s Disease Patients
Jan 13
Anavex Life Sciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Jan 6
Anavex Life Sciences Reports Fiscal 2024 Fourth Quarter Financial Results and Provides Business Update
Dec 23, 2024
Blarcamesine Receives EMA Filing Acceptance for Treatment of Alzheimer’s Disease
Dec 23, 2024
Anavex Life Sciences to Announce Fiscal 2024 Fourth Quarter Financial Results on Monday, December 23, 2024
Dec 16, 2024
Anavex Life Sciences to Report New Long-Term Oral Blarcamesine Phase IIb/III Alzheimer’s Disease Data at J.P. Morgan 2025 Healthcare Conference
Dec 9, 2024
Anavex Life Sciences to Present at the 7th Annual Evercore ISI HealthCONx Conference 2024
Dec 2, 2024
Anavex Life Sciences Announces Submission of Blarcamesine MAA for Treatment of Alzheimer’s Disease to EMA
Nov 26, 2024
Anavex Life Sciences Announces Acceptance of Peer-Reviewed Manuscript of Oral Blarcamesine Phase IIb/III Data in a Reference Alzheimer’s Disease Journal
Nov 25, 2024
Anavex’s Blarcamesine Achieves Pre-specified Efficacy in Phase IIb/III Alzheimer’s Trial: Data Presented at CTAD Conference 2024
Oct 31, 2024
Anavex Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 2024
Sep 3, 2024
Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business Update
Aug 6, 2024
Anavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024
Aug 1, 2024
Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ
May 14, 2024
Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update
May 9, 2024
Anavex Life Sciences to Present at the Noble Capital Markets Virtual Healthcare Equity Conference
Apr 11, 2024
Anavex Life Sciences to Present at the 44th Annual TD Cowen Health Care Conference
Feb 26, 2024
Anavex Life Sciences to Announce Fiscal 2024 First Quarter Financial Results on Wednesday, February 7th, 2024
Feb 1, 2024
Anavex Life Sciences Announces Grant of U.S. Patent Covering Blarcamesine (ANAVEX®2-73) for Treatment of Neurodevelopmental Disorders
Jan 8, 2024
Anavex Life Sciences Provides an Update on Rett Syndrome Program
Jan 2, 2024
Stay Connected
Follow us on social media
Newsroom
Webcast Library
Contact Us
Back to Newsroom
bottom of page
